Abstract: The present disclosure provides a method for estimating a body size and weight of a pig based on deep learning, and relates to the technical field of deep learning. The present disclosure predicts the weight of the pig by using a convolutional neural network. Relevant features are learned by the convolutional neural network, and feature engineering extraction is not needed to be established, so that extracted features are more comprehensive, and the convolutional neural network is superior to a linear model in processing of noisy data and nonlinear problems of data. Images of the pig are shot by an ordinary two-dimensional (2d) color camera.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Abstract: The present invention is directed to multispecific/multivalent molecules comprising an anti-CLL-1 binding domain.

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Abstract: Involved is pesticidal gene and use thereof, the nucleotide sequence of the pesticidal gene comprises: (a) a nucleotide sequence as shown in SEQ ID NO: 3; or (b) a nucleotide sequence as shown in SEQ ID NO: 4; or (c) an isocoding sequence of (a) or (b) which is not the nucleotide sequence as shown in SEQ ID: 22 or SEQ ID NO: 26; or (d) a nucleotide sequence which hybridizes with the nucleotide sequence as shown in (a), (b) or (c) under stringency conditions and encodes a protein having pesticidal activity. The pesticidal gene of present application is particularly suitable for expression in monocotyledonae and notably increases the expression level, stability and virulence of pesticidal protein Vip3A. At the same time, in present application, Sesamia inferens is controlled by the Vip3A protein having pesticidal activity against Sesamia inferens, which is produced in the plants.